特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
940594

新型コロナウイルス感染症(COVID-19):細胞治療、診断、治療、およびワクチン

COVID-19 Pipelines - Cell Therapies, Diagnostics, Treatments, & Vaccines

出版日: | 発行: BIOINFORMANT WORLDWIDE, LLC | ページ情報: 英文 269 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.89円
新型コロナウイルス感染症(COVID-19):細胞治療、診断、治療、およびワクチン
出版日: 2020年06月08日
発行: BIOINFORMANT WORLDWIDE, LLC
ページ情報: 英文 269 Pages
納期: 即納可能 即納可能とは
担当者のコメント
COVID-19の仕組みから疫学データ、ヘルスケア業界へのプラス面とマイナス面のインパクト、最新の開発中治療薬及びワクチン、商業利用動向、Cellベース治療法(各社別)など、2020年6月上旬時点での最新の実情を269ページの内容で網羅的にまとめた調査レポートが、BIOINFORMANT (米国)よりリリースされました。
  • 全表示
  • 概要
  • 目次
概要

当レポートは世界の新型コロナウイルス感染症(COVID-19)について調査しており、世界の統計、資金や特許、臨床試験、ワクチン・医薬品や医療関係用品の市場分析、マイナス/プラスの影響、主要研究機関や企業のプロファイル等の情報を包括的に提供しています。

目次

第1章 レポートの概要

  • レポートの声明
  • エグゼクティブサマリー
  • イントロダクション

第2章 COVID-19:構造・感染・複製・症状

  • 発生の始まり
    • 構造
    • スパイクタンパク質と酵素の構造
    • RNA依存性RNAポリメラーゼ(RdRp)の詳細
    • ウイルスのプロテアーゼ酵素の結晶構造
    • ウイルスのスパイクタンパク質の構造
    • 患者の抗体とウイルスのスパイクタンパク質との結合
    • ヒトタンパク質複合体(CUL2ZYG11B)の潜在的な結合部位
    • コロナウイルスのヒト細胞上の標的タンパク質への結合
    • ウイルスの急速な拡大の原因
  • 症状
  • 進展
  • 潜伏期間
  • 病気の期間
  • 致死率
    • 年齢別のCFR(致死率)
    • 既存の健康問題によるCFR
    • 各国および世界のCFR
  • 感染のモード
  • 臨床症例マネジメント

第3章 COVID-19:世界の統計

  • 確認された症例の世界の数の着実な増加
    • 死亡者数の急増
    • 2020年5月21日現在の地域別確認された症例数
    • 2020年5月21日現在の地域別死亡者数
    • 中国は正常に戻る
    • 中国での死亡者数
  • 最も影響を受けた主要5ヶ国
    • 米国
    • 英国
    • イタリア
    • フランス
    • スペイン
  • COVID-19と他の疾患別:死亡者数の比較
  • COVID-19症例の衰退・流れ
  • 爆発的流行を免れたアフリカ
  • 各国で実施された臨床検査数
  • 新型コロナウイルス感染症検査数の多い国:主要4ヶ国

第4章 COVID-19:調査資金

  • WHOの貢献
    • 緊急時対応基金
  • 国立衛生研究所(NIH)による調査への資金提供
  • 米国景気刺激法案による調査への資金提供

第5章 COVID-19:発行された科学論文

  • カテゴリー別:発表論文
  • 注目の雑誌記事

第6章 COVID-19に関連する可能性のあるSARS・MERSの特許

  • SARS・MERS特許のタイプ
  • 特許に記載されている主要タンパク質とウイルス感染におけるそれらの役割
  • 主要タンパク質標的に関連する特許および潜在的な薬物候補
  • 潜在的な用途を持つ既存の医薬品の特許
  • 小分子薬物候補に関連する各特許
    • 主要タンパク質に影響を与える可能性のある化合物
    • 構造類似性により同定された低分子と治療への応用
  • SARS・MERSに関連する生物製剤の特許の分布
    • SARS抗体の特許
  • SARS / MERSに関連するワクチンの特許の分布
  • SARS / MERSに関連するRNAi特許の分布

第7章 COVID-19:臨床試験情勢

  • 国/地域別
  • 研究タイプ別
    • 進行中の臨床試験におけるインターベンションタイプ
  • 開発段階別
    • 資金タイプ別
  • 進行中の臨床試験による今後の見通し

第8章 COVID-19:ヘルスケア業界におけるマイナス/プラスの影響

  • マイナスの影響
    • COVID-19世界的流行による大規模臨床試験の中断
    • 臨床試験中止の15倍もの増加
    • 臨床試験の脅威の具体例
    • 読出の遅延
    • フェーズIIIの患者の不足
    • 最も成功したピボタル試験
    • 短期ブロックバスター開発の臨床試験への脅威
    • 各手続きへの悪影響
    • 心血管系企業への影響
    • 取得の遅延
    • バイオテクノロジーフローテーションの失速
    • 製薬業界への経済的損害
  • プラスの影響
    • 協業への大きな機会
    • COVID-19市場の主導者
    • 株価を押し上げたCOVID-19イベント
    • COVID-19関連のストックライザー

第9章 COVID-19:開発中の医薬品

  • 市場に到達した最初の医薬品
    • 医薬品のスペクトル
    • 限られた時間での医薬品製造の難しさ
    • Remdesivirのジェネリック
    • COVID-19医学へのアクセスに関する懸念
  • COVID-19医薬品開発を加速するFDAのCTAP
    • スナップショット:CTAPのアクティビティ

第10章 COVID-19:新しいワクチン治療

  • 開発中のタンパク質サブユニットワクチン
  • RNAベースのワクチン
  • 非複製ウイルスベクターワクチン
  • 開発中のDNAワクチン
  • 開発中の不活化ウイルスワクチン
  • 開発中のウイルス様粒子ワクチン
  • 最短のワクチン開発
  • 追加のCOVID-19ワクチンプロジェクト
  • CEPIのワクチン基金の募集
  • ウイルスワクチンを開発するための臨床試験費用
  • ウイルスワクチンによる収益の通常パターン
  • 最近のワクチンの協業
  • 世界規模のワクチン製造企業
  • COVID-19ワクチンの大手製薬会社

第11章 COVID-19:開発における抗体療法

第12章 COVID-19:開発における抗ウイルス薬

  • COVID-19抗ウイルス治療開発の推計コスト
  • Gileadの競合
  • Remdesivir:最も早い市場参入
    • Remdesivirの結果による希望のヒント
    • Remdesivirの中間データ
    • Remdesivirの販売予測
  • Remdesivirの構造
    • Remdesivirの作用機序
  • 追加されたCOVID-19治療プロジェクト

第13章 COVID-19:再利用された薬物候補

第14章 COVID-19:開発におけるセルベースの治療法

  • COVID-19の幹細胞ベースの臨床試験の概要
    • NCT04313322 (Stem Cells Arabia)
    • NCT04366063 (Royan Institute)
    • NCT04252118 (Beijing 302 Hospital)
    • NCT04346368 (Guangzhou Institute of Respiratory Disease)
    • NCT04331613 (Chinese Academy of Sciences)
    • NCT04390139 (Banc de Sang i Teixits)
    • NCT04355728 (Camillo Ricordi)
    • NCT04299152 (Tianhe Stem Cell Biotechnologies, Inc)
    • NCT04269525 (ZhiYong Peng)
    • NCT04390152 (BioXcellerator)
    • NCT04362189 (Hope Biosciences)
    • NCT04371393 (Icahn School of Medicine/Mesoblast, Inc)
    • NCT04365101 (Celularity Incorporated)
    • NCT04367077 (Athersys, Inc)
    • NCT04365101(Celularity Incorporated)
    • NCT04367077(Athersys、Inc)
  • MSC:COVID-19に対して使用される最も適切な細胞

第15章 COVID-19:開発における医療機器

  • 人工呼吸器のスクランブル
  • 人工呼吸器の不足

第16章 COVID-19:商業利用可能な診断

  • PCRテスト(ウイルスRNAテスト)
  • 血清学検査(抗体検査)
  • 抗原検査
  • 最初のCOVID-19抗原検査
  • 家庭用COVID-19サンプルコレクションキット
  • COVID-19診断会社:主要10社
  • テストオプションの殺到

第17章 市場分析

  • 世界のCOVID-19ワクチン市場
  • COVID-19に対する抗ウイルス薬の世界の市場
  • COVID-19の診断テストの世界の市場
    • 技術別のCOVID-19テストキットの世界市場
  • アドレス可能な個人用保護具(PPE)市場
  • アドレス可能な救急医療機器市場の推計
  • その他のCOVID-19関連医療用品の世界市場
    • 素材タイプ別フェイスマスクの市場シェア
    • タイプ別手指消毒剤の世界市場シェア
  • 世界のCOVID-19治療市場

第18章 COVID-19:細胞療法会社

  • Aspire Health Science
  • Athersys, Inc.
  • AlloVir
  • Bonus BioGroup, Ltd.
  • Caladrius Biosciences
  • Capricor Therapeutics
  • Celularity
  • Celltex Therapeutics Corporation
  • Citius Pharmaceuticals, Inc.
  • Cynata Therapeutics
  • FibroGenesis
  • GC LabCell
  • Global Institute of Stem Cell Therapy and Research (GIOSTAR)
  • Healios KK
  • Hope Biosciences
  • Kimera Labs, Inc.
  • Lattice Biologics, Ltd.
  • Lineage Cell Therapeutics, Inc.
  • Mesoblast, Ltd.
  • NantKwest, Inc.
  • Orbsen Therapeutics
  • Organicell
  • Pluristem Therapeutics、Inc.
  • Tianhe Stem Cell Biotechnologies, Inc.
  • The Cure Alliance
  • Vitro Biopharma

第19章 COVID-19:臨床試験を後援するその他の企業/機関

  • AlloVirとBaylor College of Medicine
  • Biostar Stem Cell Research Institute
  • CAR-T (Shanghai) Biotechnology, Co., Ltd
  • Orgenesisの細胞ベースのワクチン
  • Peking University
  • REVTEMのCOVID-19のフェーズI / IIa
  • University of Miami:COVID-19 調査プログラム
  • Wuhan Hamilton Biotechnology

付録

  • 付録1:パンデミックの歴史
  • 付録2:国別:世界のパンデミックへの備え
  • 付録3:ソーシャルディスタンスの背後にある数学
  • 付録4:最近のCOVID-19関連ニュースの概要

図の索引

  • 社会的距離と最終的な病気の罹患率

表の索引

  • 歴史的大流行のタイムライン
  • パンデミックの基本再生産数
  • 世界のヘルスセキュリティインデックススコア
目次

This comprehensive report provides coverage of the rapidly evolving pandemic, with an emphasis on the emerging role of cell therapies in the prevention and management of the COVID-19.

While there is not yet an approved treatment for COVID-19, the scientific, medical and regulatory agencies are making heroic efforts to bring out new medicines. Numerous COVID-19 product categories have emerged, including vaccines, antibodies, antivirals, repurposed drugs, RNA-based drugs, and cell-based therapies, as well as other approaches, such as enzymes, peptides and glycoproteins. This report explores each of these product development categories in detail, presenting the products under development and timelines for them to come to market. Special attention is given to the critical role of cell-based therapies in management of the global pandemic.

Thousands of scientific articles have been published electronically or in print since the outbreak of COVID-19 began in late 2019. Patent activity around COVID-19 is surging, with many companies securing intellectual property (IP) related to the development of COVID-19 therapeutics. To a lesser degree, companies are securing IP around vaccines, diagnostic agents, and methods. This report reveals rates of COVID-19 scientific publications and presents a global breakdown of COVID-19 patent activity that includes patent type, sponsoring organization, and method of action.

Furthermore, new diagnostic tests for COVID-19 are emerging as an essential tool to track the spread of the disease, as the World Health Organization (WHO) is urging health agencies worldwide to make testing for the virus a top priority. As of May 20, 2020, the FDA granted Emergency Use Authorization (EUA) for 58 viral RNA-based tests, ten antibody-based tests, one antigen-based test and one home collection kit.

To accelerate the development of therapies against COVID-19, the repurposing of existing drugs is being explored by numerous market competitors. For example, Barcitinib is being explored because of its anti-inflammatory effect and possible ability to reduce viral entry. A specific dose of the anti-HIV combination, Lopinavir-Nitonavir, is now in clinical trials with Arbidol or Ribavirin. Remdesivir, developed by Gilead Sciences, was earlier tested in patients with Ebola virus and has shown promise in animal models for MERS and SARS. Remdesivir has reached Phase III in the U.S. and China.

Favipiravir, a purine nucleoside leading to inaccurate viral RNA synthesis, was previously developed by Toyama Chemical of Japan, and has now been approved for a clinical trial as a drug for the treatment of COVID-19. Chloroquine has shown itself to be effective in treating COVID-19 in China. Dozens of companies are rushing vaccine development and proceeding toward clinical trials. As select examples, the U.S. NIH initiated a Phase I trial in Seattle evaluating an investigational vaccine (mRNA-1273) created by NIAID scientists and their collaborators at Moderna, Inc. Sanofi and Regeneron launched a Phase II/II trial in New York evaluating the IL-6 targeted Kevzara. Inovio Pharmaceuticals is advancing its vaccine into human trials within the U.S. and intends to produce one million doses of it by the end of the year.

Globally, the healthcare industry is using every weapon in its armory to suppress the threat from the virus, including the use of living therapies such as natural killer (NK) cells, T-cells, stem cells and exosomes. While many novel approaches are being investigated, stem cells - mesenchymal stem cells (MSCs) in particular - are showing intriguing potential for the treatment of COVID-19.

MSCs are receiving attention because past studies have found the secretions from MSCs to be effective at treating inflammation and cytokine storms. From early-stage studies, it appears that MSC may exert beneficial effects, potentially by improving the lung microenvironment, inhibiting immune system over-activation, promoting tissue repair, protecting lung alveoli epithelial cells, preventing pulmonary fibrosis, or improving lung function.

Already, Athersys, Inc. has reported positive outcomes in other studies using MSCs for treating respiratory disease, and Mesoblast's Remestemcel-L has proved to be effective in treating advanced respiratory distress. Athersys and Mesoblast are enrolling for 300 and 400 patient trials, respectively - two of the largest stem cell trials to date against COVID-19. In total, at least 26 companies are exploring cell therapy products against COVID-19 and its complications.

In the recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating or preventing COVID-19. ClinicalTrials.gov has also reported at least 15 trials leveraging stem cells against COVID-19.

COVID-19 Market Trends

The aim of this report is to gather existing research on COVID-19, reveal key insights and position the reader to identify emerging market opportunities related to the Coronavirus pandemic. It provides comprehensive coverage of the outbreak, highlights global competitors involved in the fight against COVID-19, and presents product development pipelines, diagnostic testing approaches, vaccine development programs, regulatory approvals, and importantly, trend rate data for COVID-19 scientific publications, patents, and clinical trials on a worldwide basis.

With the rapidly developing nature of this global pandemic, you don't have the time to do the research. Claim this global strategic report to become immediately informed, without sacrificing hours of unnecessary research or lacking awareness of critical COVID-19 events.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CORONAVIRUS: STRUCTURE, INFECTION, REPLICATION, SYMPTOMS

  • 2.1. Start of the Outbreak
    • 2.1.1. Structure of COVID-19
    • 2.1.2. Structure of COVID-19's Spike Protein and Enzymes
    • 2.1.3. The Details of COVID-19's RNA-dependent RNA polymerase (RdRp)
    • 2.1.4. Crystal Structure of COVID-19 Virus's Protease Enzyme
    • 2.1.5. Structure of COVID-19 virus's Spike Protein
    • 2.1.6. The Binding of a Patients Antibody with COVID-19 Virus's Spike Protein
    • 2.1.7. Potential Binding Sites of Human Protein Complex (CUL2ZYG11B)
    • 2.1.8. The Binding of Coronavirus to Target Protein on Human Cell
    • 2.1.9. The Cause of COVID-19 Virus's Rapid Spread
  • 2.2. The Symptoms of COVID-19
  • 2.3. Progression of COVID-19
  • 2.4. The Incubation Period for COVID-19
  • 2.5. Duration of the Disease
  • 2.6. Case Fatality Rate
    • 2.6.1. CFR for COVID-19 by Age
    • 2.6.2. CFR for COVID-19 by Pre-Existing Health Issues
    • 2.6.3. Case Fatality Rate for Select Countries and the World
  • 2.7. Modes of COVID-19 Transmission
  • 2.8. Clinical Case Management

3. GLOBAL STATISTICS ON COVID-19

  • 3.1. The Steady Increase in Global Number of Confirmed Cases
    • 3.1.1. Steep Increase in COVID-19 Deaths
    • 3.1.2. Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020
    • 3.1.3. Number of COVID-19 Deaths by Geography as of May 21, 2020
    • 3.1.4. China Returning to Normalcy
    • 3.1.5. COVID-19 Deaths in China
  • 3.2. Top Five Most Affected Countries
    • 3.2.1. COVID-19 in the U.S.
      • 3.2.1.1. COVID-19 Deaths in the U.S.
    • 3.2.2. COVID-19 Confirmed Cases in U.K.
      • 3.2.2.1. COVID-19 Deaths in U.K.
    • 3.2.3. COVID-19 Confirmed Cases in Italy
      • 3.2.3.1. COVID-19 Deaths in Italy
    • 3.2.4. COVID-19 Confirmed Cases in France
      • 3.2.4.1. COVID-19 Deaths in France
    • 3.2.5. COVID-19 Confirmed Cases in Spain
  • 3.3. COVID-19 Deaths Compared with Deaths Due to Other Diseases
  • 3.4. The Ebb and Flow of COVID-19 Cases
  • 3.5. Africa Spared the Worst of the Pandemic
  • 3.6. Number of Laboratory Tests Conducted by Select Countries
  • 3.7. Top Four Countries with Number of COVID-Tests

4. FUNDING FOR COVID-19 RESEARCH

  • 4.1. Contributions to WHO for COVID-19 Appeal
    • 4.1.1. Contingency Fund for Emergencies
  • 4.2. National Institutes of Health (NIH) Funding for COVID-19 Research
  • 4.3. Funding for COVID-19 Research from U.S. Stimulus Bill

5. PUBLISHED SCIENTIFIC PAPERS ON COVID-19

  • 5.1. Published Papers by Category
  • 5.2. Notable Journal Articles

6. PATENTS OF SARS AND MERS WITH POSSIBLE RELEVANCE TO COVID-19

  • 6.1. Types of SARS and MERS Patents
  • 6.2. Key Proteins Described in the Patents and their Roles in Viral Infection
  • 6.3. Patents and Potential Drug Candidates Related to Key Protein Targets
  • 6.4. Patents of Existing Drugs with Potential Applications for COVID-19
  • 6.5. Selected Patents Related to Small Molecule Drug Candidates
    • 6.5.1. Compounds with Potential Effects on Key Proteins of COVID-19
    • 6.5.2. Small Molecules Identified by Structure Similarity and Therapeutic Usage
  • 6.6. Distributions of Biologics Patents Related to SARS and MERS
    • 6.6.1. Patents of SARS Antibodies
  • 6.7. Distribution of Patents of Vaccines Related to SARS/MERS
  • 6.8. Distribution of RNAi Patents related to SARS/MERS

7. CLINICAL TRIALS LANDSCAPE FOR COVID-19

  • 7.1. COVID-19 Clinical Trials by Country/Region
  • 7.2. Clinical Trials by Study Type
    • 7.2.1. Types of Interventions in the Ongoing COVID-19 Clinical Trials
      • 7.2.1.1. Proposed Pharmacological Interventions in COVID-19 Clinical Trials
      • 7.2.1.2. ATMPs under Investigation in COVID-19 Trials
  • 7.3. COVID-19 Clinical Trials by Stage of Development
    • 7.3.4. COVID-19 Clinical Trials by Funding Type
      • 7.3.4.1. Industry-Sponsored Clinical Trials against COVID-19
  • 7.4. Upcoming Readouts from Ongoing COVID-19 Clinical Trials

8. COVID-19'S NEGATIVE/POSIVE IMPACTS ON HEALTHCARE INDUSTRY

  • 8.1. Negative Impacts
    • 8.1.1. Disruption of Big Clinical Trials by COVID-19 Pandemic
    • 8.1.2. 15-Fold Increase in Clinical Trial Suspensions
    • 8.1.3. Specific Examples of Clinical Trials Threatened by COVID-19
    • 8.1.4. Delayed Readouts due to COVID-19
    • 8.1.5. Shortages of Patients for Phase III due to COVID-19
    • 8.1.6. Most Hit Pivotal Trials
    • 8.1.7. Threat to Trials of Near-Term Blockbusters
    • 8.1.8. COVID-19's Deleterious Effects on Elective Procedures
    • 8.1.9. COVID-19 Infected Cardiovascular Companies
    • 8.1.10. Delayed Acquisitions due to COVID-19
    • 8.1.11. Stalling of Biotech Flotations by COVID-19
    • 8.1.12. Financial Damages to the Pharmaceutical Industry due to COVID-19
  • 8.2. Positive Impacts
    • 8.2.1. Sizeable Opportunities for Some Collaborations
    • 8.2.2. COVID-19 Market Movers
    • 8.2.3. COVID-19 Events that Pushed the Share Prices up
      • 8.2.3.1. Johnson & Johnson
      • 8.2.3.2. Gilead Sciences
      • 8.2.3.3. Roche
      • 8.2.3.4. Sanofi
      • 8.2.3.5. BioNTech
      • 8.2.3.6. Moderna
      • 8.2.3.7. Vir Biotechnology
      • 8.2.3.8. Takeda
      • 8.2.3.9. CytoDyn
    • 8.2.4. COVID-19-Related Stock Risers

9. MEDICINES IN DEVELOPMENT FOR COVID-19

  • 9.1. The First Medicine to Reach the Market
    • 9.1.1. Spectrum of Drugs
    • 9.1.2. Difficulties in Making a Drug in Time
      • 9.1.2.1. Bargain Search
      • 9.1.2.2. Three Stages in Development
      • 9.1.2.3. Massive Demand
    • 9.1.3. Generic for Remdesivir
    • 9.1.4. Concern about Access to COVID-19 Medicine
  • 9.2. FDA's CTAP to Accelerate COVID-19 Drug Development
    • 9.2.1. CTAP's Activities in a Snapshot

10. EMERGING VACCINE TREATMENTS FOR COVID-19

  • 10.1. Protein Sub-Unit Vaccines in Development against COVID-19
  • 10.2. RNA-Based Vaccines
  • 10.3. Non-Replicating Viral Vector Vaccines
  • 10.4. DNA Vaccines in Development for COVID-19
  • 10.5. Inactivated Virus Vaccines in Development for COVID-19
  • 10.6. Virus-like Particle Vaccines in Development for COVID-19
  • 10.7. The Nearest Vaccine
  • 10.8. Additional COVID-19 Vaccine Projects
  • 10.9. CEPI's Call for Vaccine Fund
  • 10.10. Clinical Trial Costs for Developing a Viral Vaccine
  • 10.11. The Usual Pattern of Revenue Generation by Viral Vaccines
    • 10.11.1. Historical Sales of Vaccines for Previous Pandemics
    • 10.11.2. Historic Sales of H1N1 Influenza Vaccines
  • 10.12. Recent Vaccine Collaborations
  • 10.13. Companies Capable of Producing Vaccines on a Global Scale
  • 10.14. Big Pharma in COVID-19 Vaccines

11. ANTIBODY THERAPIES IN DEVELOPMENT FOR COVID-19

12. ANTIVIRAL DRUGS IN DEVELOPMENT FOR COVID-19

  • 12.1. Estimated Cost of COVID-19 Antiviral Therapeutic Development
  • 12.2. A Competitor for Gilead
  • 12.3. Remdesivir: The First to Reach the Market
    • 12.3.1. Hints of a Hope from Remdesivir Results
    • 12.3.2. Interim Data for Remdesivir
    • 12.3.3. Sales Forecast for Remdesivir
  • 12.4. Structure of Remdesivir
    • 12.4.1. Mechanism of Action of Remdesivir
  • 12.5. Additional COVID-19 Therapeutic Projects

13. REPURPOSED DRUG CANDIDATES AGAINST COVID-19

14. CELL-BASED THERAPIES IN DEVELOPMENT FOR COVID-19

  • 14.1. Brief Descriptions of Stem Cell-Based Clinical Trials for COVID-19
    • 14.1.1. NCT04313322 (Stem Cells Arabia)
    • 14.1.2. NCT04366063 (Royan Institute)
    • 14.1.3. NCT04252118 (Beijing 302 Hospital)
    • 14.1.4. NCT04346368 (Guangzhou Institute of Respiratory Disease)
    • 14.1.5. NCT04331613 (Chinese Academy of Sciences)
    • 14.1.6. NCT04390139 (Banc de Sang i Teixits)
    • 14.1.7. NCT04355728 (Camillo Ricordi)
    • 14.1.8. NCT04299152 (Tianhe Stem Cell Biotechnologies, Inc)
    • 14.1.9. NCT04269525 (ZhiYong Peng)
    • 14.1.10. NCT04390152 (BioXcellerator)
    • 14.1.12. NCT04362189 (Hope Biosciences)
    • 14.1.13. NCT04371393 (Icahn School of Medicine/Mesoblast, Inc)
    • 14.1.14. NCT04365101 (Celularity Incorporated)
    • 14.1.15. NCT04367077 (Athersys, Inc)
  • 14.2. MSCs: The Most Suitable Cells to be used Against COVID-19

15. MEDICAL DEVICES IN DEVELOPMENT FOR COVID-19

  • 15.1. The Scramble for Mechanical Ventilators
  • 15.2. Ventilator Shortages

16. COMMERCIALLY AVAILABLE DIAGNOSTICS FOR COVID-19

  • 16.1. PCR Tests (Viral RNA Tests)
  • 16.2. Serology Tests (Antibody Tests)
  • 16.3. Antigen Tests
    • 16.3.1. Number of EUAs Granted to Viral RNA Tests and Antibody Tests
    • 16.3.2. Specific Issues with Antibody Tests
    • 16.3.3. Roche's Antibody Test: Maximum Sensitivity and Specificity
  • 16.4. The First COVID-19 Antigen Test
  • 16.5. At-Home COVID-19 Sample Collection Kit
  • 16.6. Top Ten COVID-19 Diagnostic Companies
  • 16.7. The Deluge of Testing Options

17. MARKET ANALYSIS

  • 17.1. Global COVID-19 Vaccine Market
  • 17.2. Global Market for Antiviral Drugs against COVID-19
  • 17.3. Global Market for Diagnostic Tests for COVID-19
    • 17.3.1. Global Market for COVID-19 Testing Kits by Technology
  • 17.4. COVID-19 Addressable Personal Protection Equipment (PPE) Market
  • 17.5. Estimated COVID-19 Addressable Critical Care Device Market
  • 17.6. Global Market for "Other" COVID-19-Related Medical Supplies
    • 17.6.1. Market Shares of Face Masks by Type of Material
    • 17.6.2. Global Market Share for Hand Sanitizers by Type
  • 17.7. Global COVID-19 Treatment Market

18. CELL THERAPY COMPANIES JOINING FORCES AGAINST COVID-19

  • 18.1. Aspire Health Science
    • 18.1.1. Filing of Investigational New Drug
    • 18.1.2. ACT-20
  • 18.2. Athersys, Inc.
    • 18.2.1. MultiStem
    • 18.2.2. MultiStem for COVID-19
    • 18.2.3. MACOVIA Study
  • 18.3. AlloVir
    • 18.3.1. Technology
  • 18.4. Bonus BioGroup, Ltd.
    • 18.4.1. MesenCure
  • 18.5. Caladrius Biosciences
    • 18.5.1. CLBS12
    • 18.5.2. CLBS14
    • 18.5.3. CLBS16
    • 18.5.4. CLBS119 for COVID-19
    • 18.5.5. CLBS03
  • 18.6. Capricor Therapeutics
    • 18.6.1. CAP-1002
    • 18.6.2. Exosomes
    • 18.6.3. CAP-1002 for COVID-19
  • 18.7. Celularity
    • 18.7.1. IMPACT Platform
    • 18.7.2. Collaboration with United Therapeutics
  • 18.8. Celltex Therapeutics Corporation
    • 18.8.1. FDA Approval Sought
  • 18.9. Citius Pharmaceuticals, Inc.
    • 18.9.1. License Agreement with Novellus, Inc.
  • 18.10. Cynata Therapeutics
    • 18.10.1. Cynata and COVID-19
  • 18.11. FibroGenesis
    • 18.11.1. PneumoBlast
    • 18.11.2. Patent for COVID-19 Induced ARDS
  • 18.12. GC LabCell
  • 18.13. Global Institute of Stem Cell Therapy and Research (GIOSTAR)
    • 18.13.1. FDA Approval for COVID-19 Trial
  • 18.14. Healios KK
    • 18.14.1. New Treatment for ARDS
  • 18.15. Hope Biosciences
    • 18.15.1. Stem Cell Banking for Newborns
    • 18.15.2. Stem Cell Banking for Adults
    • 18.15.3. FDA Clearance for Phase II Trial of COVID-19
  • 18.16. Kimera Labs, Inc.
    • 18.16.1. Products
      • 18.16.1.1. Exosomes: A Possible Therapy for COVID-19
  • 18.17. Lattice Biologics, Ltd.
    • 18.17.1. Products
    • 18.17.2. Clinical Trial
  • 18.18. Lineage Cell Therapeutics, Inc.
    • 18.18.1. Cell Therapy Programs
      • 18.18.1.1. OpRegen
      • 18.18.1.2. OPC1
      • 18.18.1.3. VAC2
      • 18.18.1.4. COVID-19 Vaccine Development
  • 18.19. Mesoblast, Ltd.
    • 18.19.1. Remestemcel-L
    • 18.19.2. Phase II/III Trial of Remestemcel-L
  • 18.20. NantKwest, Inc.
    • 18.20.1. NantKwest and ImmunityBio against COVID-19
  • 18.21. Orbsen Therapeutics
    • 18.21.1. Orbsen's ORBCEL for COVID-19
  • 18.22. Organicell
    • 18.22.1. Organicell Flow
    • 18.22.2. Organicell Flow for COVID-19
  • 18.23. Pluristem Therapeutics, Inc.
    • 18.23.1. Pluristem's Drug Development Alliance against COVID-19
  • 18.24. Tianhe Stem Cell Biotechnologies, Inc.
  • 18.25. The Cure Alliance
    • 18.25.1. Cure Alliance's Alliance with University of Miami against COVID-19
  • 18.26. Vitro Biopharma
    • 18.26.1. Cell Therapy for COVID-19

19. OTHER COMPANIES/INSTITUTIONS SPONSORING TRIALS FOR COVID-19

  • 19.1. AlloVir and Baylor College of Medicine
  • 19.2. Biostar Stem Cell Research Institute
  • 19.3. CAR-T (Shanghai) Biotechnology, Co., Ltd
  • 19.4. Orgenesis' Cell-Based Vaccine
  • 19.5. Peking University
  • 19.6. REMSTEM's Phase I/IIa for COVID-19
  • 19.7. University of Miami-COVID-19 Research Programs
  • 19.8. Wuhan Hamilton Biotechnology

APPENDIX

  • Appendix 1: History of Pandemics
  • Appendix 1.1: A Timeline of Historical Pandemics
  • Appendix 1.2: Importing Disease
  • Appendix 1.3: Tracking Infectiousness
  • Appendix 1.4: Urbanization and Spread of Pandemics
  • Appendix 2: Global Pandemic Preparedness by Country
  • Appendix 3: The Math behind Social Distancing
  • Appendix 3.1: Effectiveness of Social Distancing
  • Appendix 4: Recent COVID-19 News in Brief
  • Appendix 4.1: Multiple Clinical Trials Test NO Gas for COVID-19
  • Appendix 4.2: U.S. Signed a Huge COVID-19 Drug Contract with Start-Up
  • Appendix 4.3: Cursory Glance at First COVID-19 Vaccine Data
  • Appendix 4.4: CEPI Grants $384 Million to Novavax's COVID-19 Vaccine
  • Appendix 4.5: Adenoviral Vector Vaccines are the Front-Runners against COVID-19
  • Appendix 4.6: The Most Effective Masks for COVID-19
  • Appendix 4.7: FDA Approval for CRISPR-Based COVID-19 Diagnostic
  • Appendix 4.8: The Antiviral EIDD-2801 to Aim at COVID-19
  • Appendix 4.9: A Loose Alliance of Competitors against COVID-19
  • Appendix 4.10: About 69 Repurposed Drugs Can Block the Replication of COVID-19
  • Appendix 4.11: Lonza to make 1 Billion Doses of Gilead's Remdesivir
  • Appendix 4.12: Merck KGaA to Ramp up Viral Vaccine Manufacturing
  • Appendix 4.13: DuPont, FeDEx and U.S. Government Teamed Up for PPE
  • Appendix 4.14: Fujifilm Tests Favipiravir against COVID-19
  • Appendix 4.15: Resolution to Produce I Million Swabs per Week
  • Appendix 4.16: BioNTech is in the Race for Vaccine

INDEX OF FIGURES

  • FIGURE 2.1: Diagrammatic Cross Sectional View of COVID-19
  • FIGURE 2.2: Structure of the Spike Protein and Enzymes of COVID-19
  • FIGURE 2.3: COVID-19 Virus's RdRp with nsp12 and nsp7
  • FIGURE 2.4: Schematic Representation of a Protease Dimer bound with two Inhibitors
  • FIGURE 2.5: The 3D Structure of the Spike Protein
  • FIGURE 2.6: The Antibody CR3022 Binding with the Spike Protein
  • FIGURE 2.7: Human Protein Complex Showing the Potential Binding Sites for the Virus
  • FIGURE 2.8: The Binding of Coronavirus to Target Protein on Human Cell
  • FIGURE 2.9: The Crystal Structure of the Enzyme ACE2
  • FIGURE 2.10: The Symptoms of COVID-19
  • FIGURE 2.11: CFR for COVID-19 in China over Time and Location
  • FIGURE 2.12: CFR for COVID-19 by Age
  • FIGURE 2.13: CFR for COVID-19 by Pre-Existing Health Issues
  • FIGURE 2.14: Case Fatality Rate for Select Countries and the World
  • FIGURE 3.1: The Steady Increase in Global Number of Confirmed Cases
  • FIGURE 3.2: Steep Increase in COVID-19 Deaths
  • FIGURE 3.3: Number of COVID-19 Confirmed Cases by Geography as of May 21, 2020
  • FIGURE 3.4: Number of COVID-19 Deaths by Geography as of May 21, 2020
  • FIGURE 3.5: Number of COVID-19 Confirmed Cases in China, Jan-22 to May-21, 2020
  • FIGURE 3.6: COVID-19 Deaths in China
  • FIGURE 3.7: COVID-19 in the U.S.
  • FIGURE 3.8: COVID-19 Deaths in the U.S.
  • FIGURE 3.9: COVID-19 Confirmed Cases in U.K.
  • FIGURE 3.10: COVID-19 Deaths in U.K.
  • FIGURE 3.11: COVID-19 Confirmed Cases in Italy
  • FIGURE 3.12: COVID-19 Deaths in Italy
  • FIGURE 3.13: COVID-19 Confirmed Cases in France
  • FIGURE 3.14: COVID-19 Deaths in France
  • FIGURE 3.15: COVID-19 Confirmed Cases in Spain
  • FIGURE 3.16: Number of COVID-19 Confirmed Cases in Africa
  • FIGURE 3.17: Top Four Countries in COVID-19 Testing
  • FIGURE 4.1: WHO's Estimated Fund to be raised in Response to COVID-19
  • FIGURE 5.1: Number of COVID-19-Related Scientific Papers
  • FIGURE 6.1: Distribution of Patents Related to SARS and MERS
  • FIGURE 6.2: Distributions of Biologics Patents Related to SARS and MERS
  • FIGURE 6.3: Distribution of Patents of Vaccines Related to SARS/MERS
  • FIGURE 7.1: Percent Share of Clinical Trials for COVID-19 by Region
  • FIGURE 7.2: Number of Clinical Trials for COVID-19 by Study Type
  • FIGURE 7.3: Percent Shares of Interventional Types in COVID-19 Clinical Trials
  • FIGURE 7.4: COVID-19 Clinical Trials by Stage of Development
  • FIGURE 7.5: COVID-19 Clinical Studies by Funding Type
  • FIGURE 8.1: Clinical Trial Terminations/Withdrawals/Suspensions
  • FIGURE 8.2: Biotech IPOs by quarter
  • FIGURE 8.3: Market Cap Gain and Loss by Size Bracket between Q4 2019 and Q1 2020
  • FIGURE 8.4: Key COVID-19 Market Movers as of April 1, 2020
  • FIGURE 9.1: Percent Share of Emerging Treatments and Vaccines for COVID-19
  • FIGURE 10.1: Percent Share of Different Types of Vaccines in Development
  • FIGURE 10.2: Pattern of Revenue Generation by Flu Vaccine of GlaxoSmithKline
  • FIGURE 10.3: Historic Sales of H5N1 Vaccines
  • FIGURE 10.4: Historic Sales of H1N1 Influenza Vaccines
  • FIGURE 10.5: World's Biggest Vaccine Makers and their Vaccine Sales
  • FIGURE 12.1: Sales of Roche's Antiviral Tamiflu
  • FIGURE 12.2: Consensus Sales Forecast for Remdesivir
  • FIGURE 12.3: Structure of Remdesivir
  • FIGURE 12.4: Mechanism of Action of Remdesivir
  • FIGURE 16.1: EUAs Granted to COVID-19 Tests
  • FIGURE 16.2: EUA for Antigen Test and Home Test Kits
  • FIGURE 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027
  • FIGURE 17.2: Global Market for COVID-19 Drugs, 2020-2027
  • FIGURE 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027
  • FIGURE 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027
  • FIGURE 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027
  • FIGURE 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027
  • FIGURE 17.7: Global Market for Face Masks, 2020-2027
  • FIGURE 17.8: Market Shares of Face Masks by Type of Material
  • FIGURE 17.9: Global Market Share for Hand Sanitizers by Type
  • FIGURE 17.10: Global Market for COVID-19 Treatment, 2020-2027
  • FIGURE 18.1: Tianhe's Stem Cell Educator Therapy
  • FIGURE App. 3.1: Social Distancing and Final Illness Attacking Rate

INDEX OF TABLES

  • TABLE 3.1: Total Confirmed Cases and Deaths from January 21 to May 21
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.1: (CONTINUED)
  • TABLE 3.2: Average Death per day due to Various Diseases
  • TABLE 3.3: Countries with Confirmed New Cases Decreasing/Increasing as of May 12
  • TABLE 3.4: Number of COVID-19 Confirmed Cases in Africa
  • TABLE 3.5: COVID-19 Tests Performed per 1,000 people by Select Country
  • TABLE 3.5: (CONTINUED)
  • TABLE 3.6: Top Four Countries in COVID-19 Testing
  • TABLE 4.1: Contributions to WHO for COVID-19 as of May 20, 2020
  • TABLE 4.1: (CONTINUED)
  • TABLE 4.2: CFE's Allocations in 2020
  • TABLE 4.3: NIH Funding for COVID-19 Research as of May 27, 2020
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.3: (CONTINUED)
  • TABLE 4.4: COVID-19 Research Fund through CARES Act in the U.S.
  • TABLE 5.1: Number of Published Papers by Category as of May 24, 2024
  • TABLE 5.2: Notable Journal Articles
  • TABLE 6.1: Key Proteins and their Roles in Viral Infection
  • TABLE 6.2: Patents and Potential Drug Candidates Related to Key Protein Targets
  • TABLE 6.3: Existing Drugs with Potential Applications for COVID-19
  • TABLE 6.4: Selected Patents Related to Small Molecule Drug Candidates
  • TABLE 6.5: Select Small Molecule Compounds in R&D to Treat COVID-19
  • TABLE 6.6: Small Molecules Identified by Structure Similarity and Therapeutic Usage
  • TABLE 6.7: Patents on Developing Therapeutic Antibodies against SARS
  • TABLE 6.7: (CONTINUED)
  • TABLE 6.7: (CONTINUED)
  • TABLE 6.7: (CONTINUED)
  • TABLE 6.8: Distribution of RNAi Patents related to SARS/MERS
  • TABLE 6.8: (CONTINUED)
  • TABLE 6.8: (CONTINUED)
  • TABLE 7.1: Number of Clinical Trials for COVID-19 by Country/Region
  • TABLE 7.2: Number of Clinical Trials for COVID-19 by Study Type
  • TABLE 7.3: Drugs used as Pharmacological Interventions in COVID-19 Trials
  • TABLE 7.3: (CONTINUED)
  • TABLE 7.4: COVID-19 Clinical Trials by Stage of Development
  • TABLE 7.5: COVID-19 Clinical Studies by Funding Type
  • TABLE 7.6: Commercial Projects in Clinical Trials for COVID-19
  • TABLE 7.6: (CONTINUED)
  • TABLE 7.6: (CONTINUED)
  • TABLE 7.6: (CONTINUED)
  • TABLE 7.7: Upcoming Readouts from Ongoing COVID-19 Clinical Trials
  • TABLE 8.1: The Ten Most Affected Biotechs Due to COVID-19 Crisis
  • TABLE 8.2: Clinical Trial Terminations/Withdrawals/Suspensions
  • TABLE 8.3: Valuable R&D Assets under Threat of Delay Due to COVID-19
  • TABLE 8.4: Commercially Sponsored Pivotal Trials due to Readout by the end of 2020
  • TABLE 8.5: Phase III Trials facing Shortages of Patients due to COVID-19
  • TABLE 8.6: The Biggest Phase III Trials that are still searching for Patients
  • TABLE 8.7: Threat to Trials of Near-Term Blockbusters
  • TABLE 8.8: COVID-19 Infected Orthopedic Companies
  • TABLE 8.9: COVID-19-Infected Cardiovascular Firms
  • TABLE 8.10: Select Pending Acquisitions in Healthcare
  • TABLE 8.10: (CONTINUED)
  • TABLE 8.11: Select COVID-19 Deals and Collaborations
  • TABLE 8.11: (CONTINUED)
  • TABLE 8.12: Key COVID-19 Market Movers as of April 1, 2020
  • TABLE 8.13: COVID-19-Related Stock Risers
  • TABLE 9.1: Current Count on Emerging Treatments and Vaccines for COVID-19
  • TABLE 10.1: Types of Vaccines in Development
  • TABLE 10.1: Protein Sub-Unit Vaccines in Development against COVID-19
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.1: (CONTINUED)
  • TABLE 10.2: RNA-Based Vaccines in Development for COVID-19
  • TABLE 10.2: (CONTINUED)
  • TABLE 10.2: (CONTINUED)
  • TABLE 10.2: (CONTINUED)
  • TABLE 10.3: Non-Replicating Viral Vector Vaccines in Development for COVID-19
  • TABLE 10.3: (CONTINUED)
  • TABLE 10.3: (CONTINUED)
  • TABLE 10.3: (CONTINUED)
  • TABLE 10.4: DNA Vaccines in Development for COVID-19
  • TABLE 10.4: (CONTINUED)
  • TABLE 10.5: Inactivated Virus Vaccines in Development for COVID-19
  • TABLE 10.6: Virus-like Particle Vaccines in Development for COVID-19
  • TABLE 10.6: (CONTINUED)
  • TABLE 10.7: Additional COVID-19 Vaccine Projects
  • TABLE 10.8: Cepi's Call for Funding
  • TABLE 10.9: Estimated Cost of Select Pandemic Clinical Programs
  • TABLE 10.10: Most Recent Collaborations in Vaccine Sector
  • TABLE 10.11: Select COVID-19 Vaccines with Big Pharma Involvement
  • TABLE 11.1: Antibody Drugs in Development for COVID-19
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 11.1: (CONTINUED)
  • TABLE 12.1: Antiviral Drugs in Development for COVID-19
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.1: (CONTINUED)
  • TABLE 12.2: Estimated Cost of COVID-19 Clinical Program (Remdesivir)
  • TABLE 12.3: Comparison of Remdesivir's Three Datasets
  • TABLE 12.4: Interim Data from Gilead's Trial (NCT04292899)
  • TABLE 12.5: Additional COVID-19 Therapeutic Projects
  • TABLE 13.1: Repurposed Drugs in Development for COVID-19
  • TABLE 13.1: (CONTINUED)
  • TABLE 13.1: (CONTINUED)
  • TABLE 13.1: (CONTINUED)
  • TABLE 14.1: Cell-Based Therapies in Development for COVID-19
  • TABLE 14.1: (CONTINUED)
  • TABLE 14.1: (CONTINUED)
  • TABLE 14.1: (CONTINUED)
  • TABLE 15.1: Medical Devices in Development for COVID-19
  • TABLE 15.1: (CONTINUED)
  • TABLE 15.2: Select Makers of Modifiable Devices Eligible for EUAs
  • TABLE 15.3: Number of FDA-Approved Ventilators between 2014 and 2020
  • TABLE 16.1: Accuracy Figures for Select COVID-19 Antibody Tests
  • TABLE 16.1: (CONTINUED)
  • TABLE 16.1: (CONTINUED)
  • TABLE 16.2: Accuracy Figures for Top Eight COVID-19 Antibody Tests
  • TABLE 16.3: Top Ten COVID-19 Diagnostic Companies
  • TABLE 16.4: Commercially Available COVID-19 Diagnostic Tests
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 16.4: (CONTINUED)
  • TABLE 17.1: Estimated Global Market for COVID-19 Vaccines, 2020-2027
  • TABLE 17.2: Global Market for COVID-19 Drugs, 2020-2027
  • TABLE 17.3: Global Market for COVID-19 Testing Kits by Geography, 2020-2027
  • TABLE 17.4: Global Market for COVID-19 Testing Kits by Technology, 2020-2027
  • TABLE 17.5: COVID-19 Impacted Market for PPE Products, 2020-2027
  • TABLE 17.6: Estimated COVID-19 Addressable Critical Care Device Market, 2020-2027
  • TABLE 17.7: Global Market for "Other" COVID-19-Related Medical Supplies, 2020-2027
  • TABLE 17.8: Global Market for COVID-19 Treatment, 2020-2027
  • TABLE App. 1.1: A Timeline of Historical Pandemics
  • TABLE App. 1.1: (CONTINUED)
  • TABLE: App. 1.2: Ro Number of Pandemics
  • TABLE App. 2.1: Global Health Security Index Score
  • TABLE App. 2.1: (CONTINUED)
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.